Pursuing the optimal strategy for immunosuppression discontinuation in children treated with rituximab for frequently relapsing, steroid-dependent nephrotic syndrome.

Rituxan (rituximab) - Roche

Pursuing the optimal strategy for immunosuppression discontinuation in children treated with rituximab for frequently relapsing, steroid-dependent nephrotic syndrome. (PubMed, Pediatr Nephrol) - Sep 18, 2026 - No abstract available
Journal • Glomerulonephritis • Nephrology • Renal Disease

http://www.ncbi.nlm.nih.gov/pubmed/42752635

Eugene Yu-Hin Chan; Georgia Malakasioti; Kjell Tullus

Sep 18, 2026